About Event

Welcome to the 13th HPAPI: Process Dev. for Highly Potent Drugs

What’s New in 2024?

With the increased complexity of novel molecules and rapid scale-up requirements, the 13th Process Development for High Potent Drugs Summit will return in 2024 with a heightened focus on:

  • How industrial hygiene, occupational toxicology can strengthen collaboration with process safety and process development group to get it right first time – from process design to equipment selection to ensure a safe operating environment for workers  
  • Integration of internal and external stakeholders throughout drug development with case studies to expedite speed-to-clinic and market cost-effectively and with GMP compliance  
  • Robust quality and risk assessment, including OEL banding, environmental monitoring and containment technology, to protect workers’ safety 

What’s In Store in 2024?

  • 15+ Brand new, data-driven case studies shared by Merck, Teva Pharmaceuticals, ADC Therapeutics, SeaGen/Pfizer, Gilead and more for you to benchmark against highly potent drug development best practice  
  • 3 deep dive workshop to help you with high potent drugs modelling using minimal data to inform faster decision making, multi-modality suites design for manufacturing flexibility and industrial and occupational hygiene considerations  
  • 3+ Panel and roundtable discussions with like-minded peers to share your day-to-day challenges but spark ideas for solutions  
  • 8+ hours of networking with 130+ industry peers and fellow attendees to build your network and relationships  
  • Unique opportunity to engage and meet 10+ selected, industry leading vendors to safeguard your high potent drug development  

5 Unmissable Takeaways:

  • Merck and Occupational Health Management Inc leading an in-depth, practical workshop on modelling HPAPI exposure using CFD and in silico technique to evaluate potency and cytotoxicity of novel molecule in R&D scale, mitigating unnecessary risks for your R&D staff 
  • SeaGen/Pfizer share how they design multi-modality suites to enable manufacturing flexibility without cross-contamination risks 
  • Teva Pharmaceuticals discuss how they overcome limited OEL banding data for compounds, and enhance cross-functional communication to mitigate risks and elevate operator safety 
  • Schedio, Dec Group, Minakem, ILC Dover and others reveal their latest solutions to help you with cost-effective, GMP-compliant containment and highly potent drug development with scale  
  • Gilead showcases how they assess containment capability to select and partner with the right equipment and technology provider, achieving GMP compliance and cost-efficiency